Jonathan has over 10 years of drug development experience. He began his career as a project statistician; designing, analyzing and interpreting clinical trials in depression and ADHD. His primary areas of expertise range from model-based meta-analysis and applied Bayesian methods to modeling time-to-event data and missing data mechanisms.
Dan Polhamus, Jonathan French, Shang-Chiung Chen, Bei Wang, Chunze Li, Dan Lu, Sandhya Girish, Jin Jin, Angelica Quartino. A Modeling and Simulation Framework for Exposure-Response Analysis in Oncology: Com- parison and Considerations of Multiple Methodologies. ACoP 6. October 2015.
Bojan Lalovic, James Rogers, Jonathan French, Mary Flack. PK-PD Analysis of PASI with Data at Boundary: BI 655066, an Anti-IL-23A mAb for the Treatment of Psoriasis. ACoP6. October 4, 2015.
Dan Polhamus, Jonathan L. French. Assessment of propensity score and Mahalanobis distance matching in the exposure-response setting. PAGE 2015.
Alanna S. Ocampo-Pellend, Marc R. Gastonguay, Jonathan L. French, Matthew M. Riggs. Model-based Meta-analysis for Development of a Population-Pharmacokinetic (PPK) Model for Vitamin D3 and its 25OHD3 Metabolite. PAGE 2015.
Jonathan French. Exposure-response modeling in oncology: technical challenges and proposed solutions. ACOP5. Las Vegas, NV. October 13, 2014.
E K Hansson, M A Amantea, P Westwood, P A Milligan, B E Houk, J French, M O Karlsson and L E Friberg. PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST. CPT: Pharmacomet. Syst. Pharmacol. 2013 2: e84
E K Hansson, G Ma, M A Amantea, J French, P A Milligan, L E Friberg and M O Karlsson. PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST. CPT: Pharmacomet. Syst. Pharmacol. 2013 2, e85.
Daniel G. Polhamus, Ph.D., James A. Rogers, Ph.D., William R. Gillespie, Ph.D., Jonathan French, Sc.D. Clinical Dementia Rating Modeling and Simulation: Joint progression of CDR and biomarkers in the ADNI cohort. AAIC 2013.
Jonathan French. Can methods based on existing models really aid decision making in non-small cell lung cancer (NSCLC) trials? PAGE 22. Glasgow, Scotland. June 12, 2013. Abstr A-06.
Jonathan French. Opportunities and Challenges of MBMA in Oncology. ACOP4. Ft. Lauderdale, FL. May 13, 2013.
Dan Polhamus, Jim Rogers, Bill Gillespie, Jonathan French, and Marc Gastonguay. From Evidence Synthesis to Trial Optimization: The adsim Package for Model-based Simulation in Alzheimer’s Disease. PAGE 21 (2012).
Elodie L. Plan, Kyle T. Baron, Marc R. Gastonguay, Jonathan L. French, William R. Gillespie, and Matthew M. Riggs. Bayesian Joint Modeling of Bone Mineral Density and Repeated Time-To-Fracture Event for Multiscale Bone Systems Model Extension. PAGE 21 (2012) Abstr 2592.
JP Ravva, M.R.Gastonguay, J.L. French, T G Tensfeldt, and H M Faessel. Quantitative Assessment of Exposure–Response Relationships for the Efficacy and Tolerability of Varenicline for Smoking Cessation. Clinical Pharmacology & Therapeutics (2010) 87 3, 336–344.